Mayer Brown is an international law firm with an intellectual property practice covering litigation, counseling, and prosecution. It handles cross-border patent enforcement and portfolio strategy across the United States, Europe, and Asia, and regularly appears before the Patent Trial and Appeal Board (PTAB), the U.S. Court of Appeals for the Federal Circuit, and in international opposition proceedings.
The firm is best known for its patent litigation practice, with prosecution playing a more strategic, business-aligned role rather than a volume-driven one. The firm’s patent activity is also largely concentrated in life sciences, which is the focus of this article.The firm has experience in sectors where IP issues intersect with regulation, particularly in life sciences and healthcare. It advises pharmaceutical and medical technology companies on matters tied to FDA processes, including exclusivity, approvals, and lifecycle management.
Mayer Brown: Global Patent Fillings
Mayer Brown’s patent prosecution work reflects a more focused practice model. Across both life sciences and broader commercial sectors, grant volumes remain relatively contained, consistent with an approach centered on high value, client specific mandates rather than large scale filing throughput. The firm’s profile points to an emphasis on strategic alignment and precision over volume driven portfolio expansion.
Mayer Brown’s activity in life sciences shows a measured but variable contribution within its overall portfolio, with periods where life sciences filings form a meaningful share of total output and other periods where activity is more limited. This pattern is consistent with the sector’s milestone driven nature, where patent filings tend to align with key stages in research, development, and regulatory progress rather than following a steady cadence. The fluctuations therefore reflect client pipeline dynamics rather than any shift in focus.
Mayer Brown’s work spans the full product lifecycle, from early drafting to later portfolio development, with decisions made upfront based on how patents may be reviewed, challenged, and used over time. This helps explain why activity appears uneven but remains closely tied to strategic objectives.
Mayer Brown: Top Technology Domains
Mayer Brown’s patent activity by technology area is strongly anchored in pharmaceuticals, which clearly dominates the firm’s work within this dataset. This concentration highlights a core focus on drug development, therapeutic innovation, and broader life sciences applications. Beyond this, transport and medical technology emerge as significant adjacent areas, indicating the firm’s involvement in sectors where engineering, devices, and regulated healthcare technologies intersect.
Other fields, including audio-visual and computer technologies, digital communication, and handling systems, form a secondary layer of activity, reflecting capabilities in software-driven and industrial innovation. Additional contributions from measurement, machinery, and materials further point to selective engagement across engineering-focused domains. Overall, the distribution suggests a practice centered on life sciences, supported by cross-sector expertise in technology and industrial applications.
Mayer Brown: Top Clients
Mayer Brown’s patent activity across its top clients shows a highly concentrated profile, anchored by a small number of key relationships. Hyundai Motors stands out as the dominant client by a clear margin, pointing to a deep and sustained advisory role, likely tied to complex innovation areas where engineering, mobility, and applied sciences intersect. A second tier of clients, including System73 and PH Health, reflects more moderate but consistent engagement. These relationships indicate exposure across biopharmaceuticals, diagnostics, and materials science, which is also reflected in the top technology domains.
Within life sciences specifically, activity is led by PH Health and Endo International, with additional contributions from Emergex and SomaScan. This aligns with Mayer Brown’s approach to patent strategy across regulation and commercialization, where prosecution is closely tied to product development stages, regulatory pathways, and market positioning. The firm focuses on building durable, high value portfolios that support long term exclusivity and commercialization goals, rather than high volume filing.
Recent developments among these clients further reflect an evolving landscape. PH Health has been active in building its brand, including the registration of the “Par Health” name in Australia. Meanwhile, Endo International has merged with Mallinckrodt, with the combined entity rebranding as Keenova Therapeutics, and Emergex has transitioned to Gylden Pharma Limited. These shifts highlight how Mayer Brown’s client base continues to evolve, while its patent strategy remains focused on aligning intellectual property with regulatory and commercial outcomes.
Mayer Brown: Top Technology Areas in Life Sciences
Mayer Brown’s work in life sciences patents is heavily centered on core medical and chemical applications. The largest share focuses on preparations for medical, dental, or hygiene-related uses (A61K), showing how foundational treatments and formulations dominate research and development. Close behind are inventions related to the therapeutic activity of chemical compounds (A61P), reinforcing the firm’s strong alignment with pharmaceutical and healthcare clients, where intellectual property strategies center on formulations, treatment methods, and drug composition.
Other areas contribute smaller but still meaningful portions, reflecting the broader ecosystem supporting life sciences. These include work on complex chemical structures (C07D), analysis of material properties (G01N), and technologies aimed at environmental adaptation (Y02A). There is also steady activity in drug delivery methods (A61M), packaging solutions (B65B), and specific classes of chemical compounds (C07C). Together, these areas illustrate a balance between direct medical applications and the supporting technologies that enable safer, more effective, and scalable innovations.
Protecting innovation across drug formulation, delivery, and patient safety
These recent patents cover innovations in how medicines are formulated, delivered, and used. They include stabilized vasopressin for critical care, a microneedle patch for fast migraine relief, and a controlled dispensing system to support proper medication use, highlighting practical solutions in healthcare.
Stable vasopressin formulations for treating hypotension
The problem
Vasopressin is commonly administered to raise blood pressure in patients experiencing hypotension, particularly in intensive care and emergency settings. However, existing vasopressin formulations are chemically unstable and prone to peptide degradation during storage.
Many conventional preparations require refrigeration, have limited shelf lives, or must be compounded shortly before administration. Over time, degradation products such as Gly9-AVP and Glu4-AVP accumulate, increasing impurity levels and reducing therapeutic reliability. These stability challenges can complicate hospital workflows, increase medication waste, and introduce risks when rapid treatment is required.
How the patent solves it
U.S. Patent No. 12,186,362 describes a stabilized vasopressin formulation designed to maintain potency and limit impurity formation during storage.
The formulation uses an acidic acetate-buffered solution, typically maintaining a pH between about 3.5 and 4, combined with diluents such as dextrose or sodium chloride. This controlled chemical environment slows peptide degradation and reduces the formation of unwanted byproducts.
The patent also describes tightly defined concentrations and optional polymeric excipients that further stabilize the peptide under stress conditions such as elevated temperatures. Together, these design choices allow the formulation to remain stable at room temperature for up to eight months, while keeping total impurity levels within acceptable limits.
Because the solution remains stable over extended storage periods, it can be packaged in ready-to-use intravenous drip bags or bottles, eliminating the need for last-minute compounding before administration.
Why it matters
Improving the stability of vasopressin formulations has practical implications for hospitals and emergency care providers. A ready-to-use, shelf-stable product simplifies logistics, reduces preparation time, and minimizes dosing errors in critical situations where rapid blood pressure control is necessary. By maintaining potency and limiting degradation products during storage, the formulation can help ensure more consistent treatment outcomes for patients experiencing severe hypotension.
The patent, titled “Vasopressin formulations for use in treatment of hypotension,” was filed on September 10, 2021, and granted on January 7, 2025. The listed inventors are Matthew Kenney, Vinayagam Kannan, Sunil Vandse, and Suketu Sanghvi. The patent is currently assigned to PH Health Ltd., which operates under the “Par Health” name linked to Par Pharmaceuticals Inc., the original filer. The patent is active and is anticipated to expire on June 2, 2037.
A microneedle patch for fast migraine relief
The problem
Migraine is a widespread and disabling neurological condition characterized by intense headache, nausea, vomiting, and sensitivity to light and sound. For decades, one of the most effective treatments has been the class of drugs known as triptans, which act as serotonin receptor agonists to relieve migraine symptoms. However, the way these drugs are delivered often limits how quickly and reliably they work.
Most triptans are administered orally, nasally, or by injection. Oral tablets are the most common option, but they can be slow to take effect and are especially unreliable during migraine attacks, when nausea, vomiting, and gastric stasis interfere with drug absorption. Nasal sprays can improve onset time but often leave an unpleasant taste and may still rely partly on gastrointestinal absorption. Injectable forms act quickly but are inconvenient and uncomfortable for many patients.
Because of these limitations, patients and physicians still lack a fast acting, well tolerated, and non oral delivery method that consistently achieves therapeutic drug levels during a migraine attack.
How the patent solves it
U.S. Patent No. 11,839,683 describes a microneedle based transdermal delivery system designed to rapidly deliver the migraine medication zolmitriptan.
The technology uses a patch containing an array of microscopic needles coated with an amorphous, rapidly dissolving zolmitriptan formulation. When applied to the skin, the microneedles painlessly penetrate the outer layer of the skin, known as the stratum corneum, allowing the drug to enter the body directly through the skin.
Because the system bypasses the gastrointestinal tract and first passes metabolism, the medication reaches systemic circulation far more quickly than with oral dosing. The drug coating dissolves within minutes, enabling therapeutic plasma levels with a Tmax as fast as two minutes and typically within thirty minutes for most subjects.
The design also supports delivery of clinically meaningful doses while maintaining lower peak plasma concentrations, which may help reduce triptan related side effects.
Why it matters
A microneedle patch could provide migraine patients with a faster and more convenient treatment option. The system combines the rapid onset typically associated with injections with the ease of use of a simple skin patch. Because it avoids oral dosing and nasal delivery, the patch remains effective even when patients experience nausea, vomiting, or impaired gastrointestinal absorption during a migraine attack. For patients seeking fast, reliable migraine relief without needles, unpleasant taste, or complex preparation, this approach could represent an important advancement in acute migraine therapy.
The patent, titled “Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines,” was filed on May 25, 2021, and granted on December 12, 2023.. The listed inventors are Mahmoud Ameri, Donald Kellerman, Peter E. Daddona, and Yi Ao. The patent is assigned to Emergex USA Corp, now operating as Gylden Pharma following its corporate rebranding, and is expected to remain active until February 21, 2037.
A smart dispensing system to ensure medications are taken safely
The problem
Medication non adherence is one of the most persistent and costly challenges in healthcare. Many patients do not take their medications exactly as prescribed, which can lead to treatment failure, avoidable complications, and increased hospitalizations.
Studies cited by Express Scripts estimate that improper medication use contributes to hundreds of billions of dollars in avoidable healthcare costs each year. The problem is especially serious among older adults, who often take multiple medications simultaneously and may also use supplements or non-prescribed drugs that are not fully tracked by clinicians.
In most cases, medication management depends heavily on patient self administration. Physicians prescribe medications with static instructions, and pharmacies dispense them in standard packaging. After that point, clinicians have little visibility into whether medications are taken correctly, stored properly, or combined safely with other substances. This lack of oversight can lead to adverse drug events, missed doses, incorrect timing, and dangerous drug interactions, many of which are preventable.
How the patent solves it
U.S. Patent No. 10,660,824 describes an intelligent drug dispensing ecosystem designed to actively manage medication safety and adherence.
At the center of the system is a tamper resistant dispensing device that stores oral medications and controls when doses can be accessed, working alongside a mobile app, biometric authentication, and a centralized support platform. Before dispensing, drug specific algorithms evaluate prescription rules together with real time patient data, including physiological, behavioral, environmental, and storage factors.
If risks such as early dosing, unsafe combinations, or improper storage are detected, the device remains locked even at scheduled times. Secure connectivity enables healthcare providers to intervene, adjust prescriptions, and address safety concerns in real time.
Why it matters
Medication adherence programs often rely on reminders or education, but this system takes a more proactive approach by controlling access to medication based on safety and effectiveness.
By preventing unsafe dosing and reinforcing proper use, it can reduce adverse drug events, avoidable hospitalizations, and improve outcomes, especially for patients with complex regimens. More broadly, it helps ensure medications are not just prescribed, but taken correctly and safely.The patent, titled “Devices, system and method to control the delivery of oral medications to ensure they are efficacious, taken as prescribed, and to avoid unwanted side effects,” was filed on August 11, 2016, and granted on May 26, 2020. The listed inventor is Edmund L. Valentine. The patent remains active and is expected to expire on August 11, 2036.